A Study of Subcutaneously Administered RO7845860 in Participants With Relapsing Multiple Sclerosis (NOVA-BEAM)
An Open-Label, Multicenter, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered RO7845860 in Participants With Relapsing Multiple Sclerosis
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and, pharmacodynamics (PD) of subcutaneously administered RO7845860 in participants with relapsing multiple sclerosis (RMS).
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
研究連絡先のバックアップ
- 名前:Reference Study ID Number BP46580 https://forpatients.roche.com/ No attachments to email below.
- 電話番号:888-662-6728 (U.S. and Canada)
- メール:global-roche-genentech-trials@gene.com
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Diagnosis of RMS (i.e., relapsing-remitting multiple sclerosis [RRMS] or a secondary progressive multiple sclerosis [SPMS] where patients still experience relapses) in accordance with the revised 2017 McDonald Criteria.
-
No relapse for 30 days prior to screening and neurologically stable with no relapse during screening.
-
Expanded Disability Status Scale (EDSS) score at screening (historical EDSS not older than 6 months may be used), from 0 to 6.5 inclusive.
-
From Part 2 onwards,
- at least two documented clinical relapses within the last 2 years prior to screening, or
- one documented clinical relapse in the year prior to screening or
- one documented clinical relapse together with signs of Magnetic Resonance Imaging (MRI) activity (any T1 Gd+ and/or new or enlarging T2 lesion) between 12 and 24 months prior to screening.
-
Documented MRI of brain with abnormalities consistent with Multiple Sclerosis (MS) at screening.
Exclusion Criteria:
-
History of primary progressive multiple sclerosis (PPMS) at screening.
-
Any of the following laboratory parameters:
- CD4 levels below lower limit of normal (LLN)
- Absolute neutrophil count (ANC) levels below LLN
- Serum immunoglobulin G (IgG) levels below LLN
- Absolute lymphocyte count < 1000 cells per microliter (μL)
- B-cell levels below LLN
-
Known presence of other neurologic disorders that may mimic MS, including but not limited to, neuromyelitis optica spectrum disease, myelin oligodendrocyte antibody associated disease, Lyme disease, untreated vitamin B-12 deficiency, cerebrovascular or spinal vascular disorders, and untreated hypothyroidism.
-
Clinically significant cardiac, metabolic, hematologic, hepatic, immunologic, urologic, endocrinologic, neurologic, pulmonary, dermatologic, psychiatric, allergic, renal or other major diseases that in the investigator's judgement, may affect interpretation of study results or participant safety.
-
Prior treatment with Chimeric antigen receptor (CAR) T-cell therapy, gene-therapy product, total body irradiation, bone marrow transplantation, allograft organ transplant, or hematopoietic stem cell transplant at any point.
-
Inability to complete an MRI scan (contraindications for MRI, including but not restricted to, pacemaker, cochlear implants, intracranial vascular clips, surgery within 6 weeks prior to screening coronary stent implanted within 8 weeks prior to the time of the intended MRI, etc.) or contraindication to gadolinium administration.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Part 1: Single Ascending Dose Escalation
Participants will receive single dose of RO7845860. |
Participants will receive RO7845860 as an subcutaneous (SC) injection per the schedule in the protocol. |
|
実験的:Part 2: Multiple Ascending Dose Escalation
Participants will receive multiple doses of RO7845860. |
Participants will receive RO7845860 as an subcutaneous (SC) injection per the schedule in the protocol. |
|
実験的:Part 3: Dose Expansion
Participants will receive multiple doses of RO7845860. |
Participants will receive RO7845860 as an subcutaneous (SC) injection per the schedule in the protocol. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Part 1, 2 and 3: Incidence and Severity of Adverse Events (AEs)
時間枠:From Baseline up to approximately Week 96
|
From Baseline up to approximately Week 96
|
|
Part 1, 2 and 3: Change From Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)
時間枠:From Baseline up to approximately Week 96
|
From Baseline up to approximately Week 96
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
Part 1, 2 and 3: Serum Concentration of RO7845860
時間枠:At prespecified timepoints from Baseline up to approximately Week 96
|
At prespecified timepoints from Baseline up to approximately Week 96
|
|
Part 1, 2 and 3: Percentage of Participants Achieving B-Cell Levels Below the Lower Limit of Quantitation in Blood as per Employed High-Sensitive Flow Cytometry Assay
時間枠:From Baseline up to approximately Week 96
|
From Baseline up to approximately Week 96
|
|
Part 1, 2 and 3: B-Cell Levels Over Time in Blood
時間枠:From Baseline up to approximately Week 96
|
From Baseline up to approximately Week 96
|
|
Parts 1, 2 and 3: Median Time to Repletion of B-Cells in Blood to the Lower Limit of Normal or to the Detection Limit of the B-cell Assays
時間枠:From Baseline up to approximately Week 96
|
From Baseline up to approximately Week 96
|
|
Parts 2 and 3: Change From Baseline in B-Cell Levels in Cerebrospinal Fluid (CSF)
時間枠:From Baseline up to approximately Week 96
|
From Baseline up to approximately Week 96
|
|
Parts 1, 2 and 3: Prevalence and Incidence of Anti-drug Antibodies (ADAs) to RO7845860
時間枠:From Baseline up to approximately Week 96
|
From Baseline up to approximately Week 96
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Clinical Trials、Hoffmann-La Roche
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- BP46580
- 2026-526353-34-00 (その他の識別子:EU CT Number)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。